112 related articles for article (PubMed ID: 1768780)
1. Preliminary experience with intraperitoneal catheters in the treatment of ovarian cancer.
Mählck CG; Rogo KO; Stendahl U
In Vivo; 1991; 5(2):119-21. PubMed ID: 1768780
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cisplatin-based chemotherapy for primary treatment of epithelial ovarian cancer.
Del Prete SA; Ryan SP; Nelson JH
Conn Med; 2001 Feb; 65(2):71-5. PubMed ID: 11265604
[TBL] [Abstract][Full Text] [Related]
3. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.
Arts HJ; Willemse PH; Tinga DJ; de Vries EG; van der Zee AG
Gynecol Oncol; 1998 Apr; 69(1):32-5. PubMed ID: 9570995
[TBL] [Abstract][Full Text] [Related]
4. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer.
Meunier F; van der Auwera P; Aoun M; Piccart M; Sculier JP
Scand J Infect Dis Suppl; 1990; 72():26-8. PubMed ID: 2151063
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
7. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
[TBL] [Abstract][Full Text] [Related]
8. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
9. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1873-5. PubMed ID: 2697191
[TBL] [Abstract][Full Text] [Related]
11. Complications associated with intraperitoneal chemotherapy catheters.
Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of complications associated with catheter intraperitoneal chemotherapy of ovarian carcinoma].
Wei LH; Qian HN; Li WF
Zhonghua Fu Chan Ke Za Zhi; 1994 Dec; 29(12):732-4, 762-3. PubMed ID: 7712902
[TBL] [Abstract][Full Text] [Related]
14. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Malmström H; Carstensen J; Simonsen E
Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
[TBL] [Abstract][Full Text] [Related]
15. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
16. [Tumor chemotherapy of ovarian cancer patients in advanced age].
Behling H; Schirmer A; Krafft W; Brückmann D
Zentralbl Gynakol; 1988; 110(2):95-101. PubMed ID: 3364065
[TBL] [Abstract][Full Text] [Related]
17. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
